ADC Therapeutics (NYSE:ADCT – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare ADC Therapeutics to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.
Analyst Ratings
This is a summary of recent ratings and price targets for ADC Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADC Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
| ADC Therapeutics Competitors | 9931 | 15323 | 45717 | 1605 | 2.54 |
ADC Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 289.11%. As a group, “Biotechnology” companies have a potential upside of 133.70%. Given ADC Therapeutics’ higher possible upside, research analysts plainly believe ADC Therapeutics is more favorable than its peers.
Earnings & Valuation
This table compares ADC Therapeutics and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ADC Therapeutics | $81.36 million | -$142.62 million | -2.47 |
| ADC Therapeutics Competitors | $715.39 million | $10.31 million | -18.30 |
ADC Therapeutics’ peers have higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
ADC Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, ADC Therapeutics’ peers have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Profitability
This table compares ADC Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADC Therapeutics | -95.73% | N/A | -28.26% |
| ADC Therapeutics Competitors | -12,319.70% | -407.93% | -30.95% |
Summary
ADC Therapeutics peers beat ADC Therapeutics on 7 of the 13 factors compared.
ADC Therapeutics Company Profile
ADC Therapeutics is a biotechnology company headquartered in Epalinges, Switzerland. It develops antibody-drug conjugates (ADCs), medicines designed to use antibodies to deliver cell-killing agents to cancer cells. Its research has focused on blood cancers and solid tumors. The company’s lead product, ZYNLONTA (loncastuximab tesirine-lpyl), is an ADC that targets CD19. In the United States, it is approved for adults with relapsed or refractory large B-cell lymphoma after they have received two or more prior systemic treatments.
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
